Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of rituximab, high-dose
ara-c and dexamethasone (r-had) alone or in combination with bortezomib in patients with
relapsed or refractory mantle cell lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
Dr. M. Dreyling (co-chairman) Prof. Dr. M. Dreyling (co-chairman)
Collaborators:
ClinAssess GmbH GELARC Service de Pharmacovigilance, Pierre Benite Klinikum der Universitaet Muenchen, Grosshadern